RG
ATXS

Redmile Group’s Astria Therapeutics ATXS Stock Holding History

Redmile Group’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-269,078
Closed -$1.44M – 50
2025
Q1 		$1.44M Sell
269,078
-77,200
-22% -$540K 0.14% 52
2024
Q4 		$3.1M Buy
346,278
+35,394
+11% +$376K 0.22% 49
2024
Q3 		$3.42M Buy
+310,884
New +$3.46M 0.2% 52

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Redmile Group's ATXS Position: Q2 2025 in Review

Redmile Group sold out of Astria Therapeutics (ATXS) in Q2 2025, closing a stake of 269,078 shares — an estimated $1.44M sold.

Redmile Group first reported a position in ATXS in Q3 2024 and held it in 3 quarters. The position peaked at $3.42M in Q3 2024. 105 funds tracked by Wall St. Rank hold ATXS as of Q2 2025.

  • Redmile Group reported no remaining Astria Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Redmile Group sold 269,078 Astria Therapeutics shares in Q2 2025, an estimated $1.44M.
  • Redmile Group first reported a position in Astria Therapeutics in Q3 2024 and held it in 3 quarters.
  • Redmile Group's Astria Therapeutics position peaked at $3.42M in Q3 2024.
  • 105 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2025.

Based on Redmile Group's 13F filing for Q2 2025, filed 14 Aug 2025.